Assertio Holdings, Inc. Announces Executive Changes
December 15, 2020 at 09:22 am EST
Share
Effective as of December 14, 2020, Todd N. Smith, President and a director of Assertio Holdings, Inc. voluntarily resigned as President and as a director of the Company. Mr. Smith's decision to resign as a director does not arise from any disagreement with the Company on any matter relating to the Company's operations, policies or practices. Effective upon Mr. Smith's resignation, the Board of Directors of the Company elected Daniel A. Peisert to serve as the Company's President and appointed him as a director. Mr. Peisert has served as Assertio's Executive Vice President since May 2020 and Chief Financial Officer since December 2018. Mr. Peisert previously served as Assertio's Senior Vice President, Business Development from August 2018 to November 2018 and Assertio's Vice President, Business Development from September 2017 to August 2018. Effective as of December 14, 2020, Mark Strobeck, Ph.D., Executive Vice President and Chief Operating Officer of the Company voluntarily resigned as Executive Vice President and Chief Operating Officer of the Company. On December 14, 2020, Timothy Walbert voluntarily resigned from his position as a director of the Company, effective immediately.
Assertio Holdings, Inc. is a commercial pharmaceutical company offering differentiated products to patients. The Company has built its commercial portfolio through acquisition or licensing of approved products. Its comprehensive commercial capabilities include marketing through both a sales force and a non-personal promotion model, market access through payor contracting and trade and distribution. The Companyâs primary marketed products include ROLVEDONTM (eflapegrastim-xnst) injection for subcutaneous use, INDOCIN (indomethacin) Suppositories, INDOCIN (indomethacin) Oral Suspension, Sympazan (clobazam) oral film, Otrexup (methotrexate) injection for subcutaneous use, SPRIX (ketorolac tromethamine) Nasal Spray, CAMBIA (diclofenac potassium for oral solution) and Zipsor (diclofenac potassium) Liquid filled capsules. INDOCIN (indomethacin) Suppositories and INDOCIN (indomethacin) Oral Suspension products are nonsteroidal anti-inflammatory drugs (NSAID).
ASSERTIO HOLDINGS, INC. 
